Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial

The LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complica...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2022-05, Vol.32 (5), p.1288-1291
Main Authors: Noto, Davide, Petta, Salvatore, Giammanco, Antonina, Spina, Rossella, Cabibbi, Daniela, Porcasi, Rossana, Caldarella, Rosalia, Ciaccio, Marcello, Muratore, Roberto, Cefalù, Angelo B., Craxi, Antonio, Averna, Maurizio
Format: Article
Language:English
Subjects:
Biopsy - adverse effects
Double-Blind Method
Ezetimibe
Ezetimibe - adverse effects
Humans
Life Style
Liver biopsy
Non-alcoholic Fatty Liver Disease - diagnosis
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic steatohepatitis
Randomized controlled trial
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complications of non-alcoholic steatohepatitis (NASH) evaluated by liver histology. Forty patients with NASH ascertained by histology were randomly allocated on the two study groups and subjected to a follow-up of 52 weeks, when they underwent a second liver biopsy. Main composite end point (EP) was based on the histological improvement in the severity of NASH. Thirty patients completed the study, Eze treatment was not able to improve the primary EP in comparison with placebo, with and odds ratio of 1.029 (0.18–6.38), p = 0.974. Treatment emergent adverse events registered during the study were not more prevalent in the treatment arm. ezetimibe administered on top of lifestyle and dietary modification failed to improve the histology of NASH in comparison with lifestyle and dietary modification alone. ClinicalTrial.gov: NCT01950884. •Ezetimibe is lipid lowering drug able to promote cholesterol efflux from the liver.•Ezetimibe has been proposed to treat NAFLD.•Ezetimibe use in NAFLD has been tested in a randomized controlled trial.•Ezetimibe failed to improve NAFLD features measured by liver biopsies.•Diet and Lifestyle remain the main therapeutic options for NAFLD.
ISSN:0939-4753
1590-3729
DOI:10.1016/j.numecd.2022.01.024